Lifileucel (LN‐144) is an autologous TILs therapy that uses TILs from patient's tumor‐tissue and being expanded ex vivo to produce polyclonal patient‐specific TILs (mix of CD8+ and CD4+ T cells) [485]. Here, CD4 is linked to neoplasm.